

.....
(Original Signature of Member)

119TH CONGRESS
1ST SESSION

H. R. _____

To increase funding for cancer research by the National Cancer Institute to be more in proportion to the mortality rates of cancer.

IN THE HOUSE OF REPRESENTATIVES

Mr. FITZPATRICK introduced the following bill; which was referred to the Committee on _____

A BILL

To increase funding for cancer research by the National Cancer Institute to be more in proportion to the mortality rates of cancer.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Knock Out Cancer
5 Act” or the “KO Cancer Act”.

6 **SEC. 2. FINDINGS.**

7 Congress finds the following:

1 (1) Cancer is one of the leading causes of death
2 in the world and has touched nearly every life, either
3 directly or indirectly.

4 (2) Cancer is the cause of nearly 1 out of every
5 4 deaths in the United States, since 2000 totaling
6 over 15 million American lives.

7 (3) Efforts to increase awareness of cancer
8 symptoms among patients and clinicians would lead
9 to earlier detection and improvements in survival
10 rates.

11 (4) Scientific understanding and research lead
12 to innovations in effective treatments, controls, and
13 cures for cancer.

14 (5) The National Cancer Institute has been a
15 leader in finding medical breakthroughs for treat-
16 ment and therapies for cancer patients.

17 (6) Through substantial investment in cancer
18 research, potentially even the tripling of necessary
19 funding, the United States will be best able to ad-
20 dress the mortality rates of cancer and the impacts
21 on the patient population.

22 **SEC. 3. INCREASING NCI BUDGET FOR CANCER RESEARCH.**

23 To conduct or support cancer research, there is here-
24 by appropriated, for each of fiscal years 2026 through
25 2030, to the National Cancer Institute, out of amounts

1 in the Treasury not otherwise appropriated, an amount
2 that is equal to 25 percent of the total amount appro-
3 priated to the National Cancer Institute for fiscal year
4 2022, to remain available until expended. Amounts appro-
5 priated pursuant to the preceding sentence shall be in ad-
6 dition to amounts otherwise made available to the Na-
7 tional Cancer Institute.

8 **SEC. 4. REPORT TO CONGRESS ON CANCER DRUG SHORT-**
9 **AGES.**

10 (a) **STUDY.**—The Secretary of Health and Human
11 Services, acting through the Commissioner of Food and
12 Drugs, in collaboration with such other agencies as the
13 Secretary deems necessary, shall study the reasons for
14 cancer drug shortages, including—

15 (1) economic reasons;

16 (2) supply chain failures;

17 (3) delays and other complications relating to—

18 (A) the development of cancer drugs; and

19 (B) the approval of such drugs by the
20 Food and Drug Administration; and

21 (4) insufficient generic drugs and biosimilar bi-
22 ological products.

23 (b) **REPORT.**—

24 (1) **IN GENERAL.**—Not later than 1 year after
25 the date of enactment of this Act, the Secretary of

1 Health and Human Services, acting through the
2 Commissioner of Food and Drugs, shall complete
3 the study under subsection (a) and submit a report
4 to the appropriate committees of the Congress on
5 the results of such study.

6 (2) RECOMMENDATIONS.—The report under
7 paragraph (1) shall include recommendations for ad-
8 dressing the reasons for cancer drug shortages.